Oral delivery platform for biopharmaceuticals.
Lead product in phase 1b trials for Oral Mucositis.
Pharmaceutical company implementing novel concepts for the treatment of mental disorders.
Lead product in pre-clinic for neuropathic pain.
Marine biotechnology company developing new biologically active products from marine microbes.
Portfolio of pharmaceuticals to treat bacterial infections and inflammation in preclinical stage
Avantium is a leading renewable chemicals company that develops and commercializes next generation biobased plastics and chemicals.
Brain-targeted drug delivery company, which uses its platform technologies to synergize with established and marketed drugs.
Lead product in phase I for the treatment of brain tumors.
Molecular diagnostics company developing novel diagnostics technology platforms for low to highly multiplexed detection of molecular-based biomarkers. Lead product in late stage development.
Biopharmaceutial company developing novel targeted medicines to treat different cancers. Lead product is an oral dual selective FGF/VEGF protein kinase inhibitor in phase 1b.
Next generation antibody company developing improved therapeutic antibodies and antibody fragments based on its unique Modular Antibody Technology.
Medical device company developing Eye diagnostics. Its lead product, the EasyScan, is a fast and easy to use non-mydriatic retina imaging camera for the diagnosis of Diabetic Retinopathy. The EasyScan has received CE and FDA approval at the end of 2011 as is nowadays sold in Asia, Europe and North and South America.
Heat-shock protein based therapeutics for lysosomal storage diseases. Lead product in pre-clinical stage.
Biopharmaceutical company developing decoy proteins based on human chemokines which act to block inflammatory processes. The company’s lead product PA401 is a decoy IL-8 protein which is in preclinical development for COPD.
Developing an Enzyme replacement therapy for Morbus Morquio.
Lead product in manufacturing.